Lilly, for its part, has published ACHIEVE-3 data showing that orforglipron at its highest dose outperformed oral semaglutide 14 mg on both A1C reduction and weight loss in adults with type 2 diabetes, though this comparison involved the Rybelsus-equivalent doses rather than the obesity-approved dose levels
Your decision to pursue GLP-1 therapy should reflect an informed discussion with your healthcare team, consideration of your personal gastrointestinal history, and confidence in your ability to recognize and respond to warning signs
Prior authorization criteria typically require measured height and weight, a calculated body mass index consistent with the labeled population, diagnosis codes for weight-related conditions, and documentation of prior diet and activity interventions
Shanghai Municipal Science and Technology Major Project 2019SHZDZX02 (H.E.X.)
Is Semaglutide the same as Tirzepatide